Which are the 10 hottest biotech stocks on the ASX?

Summary

  • The biotech industry comprises companies using living organisms to develop drugs and diagnostics to treat various diseases.
  • The ongoing scientific advances are presenting tremendous opportunities for market participants in the biotech space.
  • The best biotech companies boast a strong product portfolio, impressive product pipeline and advanced clinical development programs.

The biotechnology sector includes stocks that use living organisms, such as bacteria, to develop drugs to treat a range of indications. These products must undergo rigorous, costly, and time-consuming clinical trials to receive authorisation from a regulatory authority. This signifies that the investors might need to wait for years to know if a product under development will start paying back.

The industry comprises small start-ups and large, well-established corporations aiming to develop multiple drug molecules and technologies. Besides, scientific advances are generating new ways that were only imaginable earlier to treat and prevent several diseases. The biotech sector presents tremendous opportunities for investors who are looking for long-term returns.

MUST READ: Looking for healthcare dividend stocks? Here are the top five players

Source: Copyright © 2021 Kalkine Media

The COVID-19 pandemic has generated significant opportunities for biotechnology players to develop potential treatments and vaccines. Several biotech players have moved their focus on developing vaccines and treatments for SARS-CoV-2 to their product pipeline with the pandemic.

With this backdrop, let’s take a look at the 10 best biotech stocks on the ASX-

ALSO READ: Which are the Top 10 blue-chip stocks on the ASX?

Actinogen Medical Limited (ASX:ACW)

ASX-listed biotechnology firm Actinogen Medical is developing a revolutionary therapy for cognitive impairment associated with neurological indications due to modifications of increased levels of cortisol inside the brain cells. The lead drug candidate of Actinogen Medical is Xanamem® which has been designed to block the production of cortisol (stress hormone) in the brain.

Bionomics Ltd (ASX:BNO)

ASX-listed clinical-stage company Bionomics Ltd is leveraging its proprietary platform technologies to discover and develop innovative drug candidates. The lead drug candidate of Bionomics is BNC210 which is currently under development for the treatment of posttraumatic stress disorder (PTSD). Besides, Bionomics has a strategic collaboration with Merck & Co., Inc with two drugs in early-stage trials.

Incannex Healthcare Limited (ASX:IHL)

Clinical stage pharmaceutical player Incannex Healthcare is developing exclusive medicinal cannabis products and psychedelic medicine therapies. IHL has a robust patent filing strategy as it develops its therapies in conjunction with its medical advisory board.

Source: Copyright © 2021 Kalkine Media

Antisense Therapeutics Ltd (ASX:ANP)

Antisense Therapeutics is an Australian biotechnology firm engaged in developing and commercialising antisense pharmaceuticals for unmet medical needs in rare diseases. The Company is developing a CD49d receptor antisense inhibitor named ATL1102.

DO READ: How are medical chatbots transforming patient care?

Telix Pharmaceuticals (ASX:TLX)

Melbourne-headquartered biopharmaceutical firm Telix is focused on the development of therapeutic and diagnostic products using Molecularly Targeted Radiation. The Company is developing a portfolio of clinical-stage products to address the significant unmet medical need in cancer and rare diseases.

IDT Australia Ltd (ASX:IDT)

ASX-listed pharmaceutical manufacturing firm IDT Australia has extensive experience in developing high potency and high containment pharmaceutical formulations. The facilities of

IDT facilities are cGMP compliant and are frequently audited by the US Food and Drug Administration (FDA) and Australian Therapeutic Goods Administration (TGA)

Immutep Ltd (ASX:IMM)

Globally active biotechnology firm Immutep is a leader in developing immunotherapeutic (LAG-3 related) products for the treatment of cancer and autoimmune indications. Immutep is developing product candidates IMP321 and IMP761 with its large pharmaceutical partners.

Race Oncology Ltd (ASX:RAC)

ASX-listed Race Oncology is developing Bisantrene, a potent inhibitor of the FTO (Fatso/Fat mass and obesity-associated) protein. The Company is exploring Bisantrene as a new treatment for renal cell carcinoma (clear cell) and melanoma.

GOOD READ: Race Oncology joins hands with Trialog for Phase 2 AML trial in Israel

Source: Copyright © 2020 Kalkine Media

Patrys Limited (ASX:PAB)

Melbourne-based novel antibody technologies developer Patrys Limited is focused on the development of the deoxymab platform as therapies for several different cancers. The deoxymab platform of PAB is based on cell-penetrating antibodies, for example, 3E10 antibody initially isolated from a mouse model of systemic lupus erythematosus (SLE).

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)

NeuroScientific Biopharmaceuticals is engaged in the development of peptide-based pharmaceutical compounds that target several neurodegenerative indications with high unmet medical need. The product portfolio of the Company comprises Emtin peptides including EmtinB, EmtinAc, EmtinAn, and EmtinBn.

MUST READ: Is cloud computing the future of all businesses?

Source: Copyright © 2021 Kalkine Media (Data Source: ASX, as of 22 June 2021)


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK